Why the study?
Do beta-adrenoceptor blockers and thrombolytic agents improve outcomes safely in elderly patients with heart failure or acute myocardial infarction?
Do beta-adrenoceptor blockers and thrombolytic agents improve outcomes safely in elderly patients with heart failure or acute myocardial infarction?
This review highlights the need to understand the efficacy and safety of beta-blockers and thrombolytics specifically in elderly patients with heart failure and acute myocardial infarction.
Evidence gaps limit beta-blocker and thrombolytic guidance in elderly HF/AMI; leaves open optimal strategies pending dedicated trials.
Beta-adrenoceptor blockers and thrombolytic agents are of established value in the pharmacological management of heart failure and ST-elevation myocardial infarction, respectively. However, there is uncertainty as to whether these therapeutic strategies can be safely and effectively adopted in elderly patients with comorbidities, particularly in old-old individuals. This review focuses on these trials and the age-related efficacy and safety of these drugs.
No takes yet. Share an insight, caveat, or question.
Mangoni et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: